Quent Capital LLC Acquires 4,068 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Quent Capital LLC lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 83.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 8,916 shares of the company’s stock after buying an additional 4,068 shares during the quarter. Quent Capital LLC’s holdings in 10x Genomics were worth $173,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Westwood Holdings Group Inc. bought a new stake in shares of 10x Genomics during the first quarter valued at approximately $939,000. Swedbank AB bought a new stake in shares of 10x Genomics during the first quarter valued at approximately $675,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of 10x Genomics during the first quarter valued at approximately $3,647,000. Bellevue Group AG increased its position in shares of 10x Genomics by 5.2% during the first quarter. Bellevue Group AG now owns 308,311 shares of the company’s stock valued at $11,571,000 after acquiring an additional 15,138 shares in the last quarter. Finally, Bamco Inc. NY increased its position in shares of 10x Genomics by 59.4% during the first quarter. Bamco Inc. NY now owns 314,862 shares of the company’s stock valued at $11,817,000 after acquiring an additional 117,300 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded up $0.54 on Tuesday, hitting $18.87. 1,246,205 shares of the company’s stock were exchanged, compared to its average volume of 1,657,819. The company has a 50-day simple moving average of $19.76 and a 200-day simple moving average of $30.70. The stock has a market capitalization of $2.25 billion, a PE ratio of -8.48 and a beta of 1.84. 10x Genomics, Inc. has a 1 year low of $15.28 and a 1 year high of $57.90.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 4,877 shares of 10x Genomics stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the transaction, the chief executive officer now owns 889,641 shares in the company, valued at approximately $21,618,276.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Serge Saxonov sold 4,877 shares of 10x Genomics stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the transaction, the chief executive officer now owns 889,641 shares in the company, valued at approximately $21,618,276.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Justin J. Mcanear sold 2,936 shares of 10x Genomics stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $71,344.80. Following the transaction, the chief financial officer now owns 146,203 shares in the company, valued at approximately $3,552,732.90. The disclosure for this sale can be found here. Insiders have sold 11,900 shares of company stock worth $289,170 in the last 90 days. 10.03% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TXG shares. Bank of America reduced their price target on shares of 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, July 18th. JPMorgan Chase & Co. cut shares of 10x Genomics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $40.00 to $20.00 in a report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft cut shares of 10x Genomics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $55.00 to $25.00 in a report on Wednesday, July 10th. Guggenheim restated a “neutral” rating on shares of 10x Genomics in a report on Tuesday, June 25th. Finally, Barclays dropped their target price on shares of 10x Genomics from $36.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus target price of $33.31.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.